No association of CSF biomarkers with APOE 4, plaque and tangle burden in definite Alzheimer's disease
Authors:
- Kristel SleegersKSKristel Sleegers
- Patrick CrasPCPatrick Cras
- Nathalie BrouwersNBNathalie Brouwers
- Sally SerneelsSSSally Serneels
- Evelyn De LeenheirELEvelyn De Leenheir
- Jean-Jacques MartinJMJean-Jacques Martin
- Eugeen VanmechelenEVEugeen Vanmechelen
- Christine Van BroeckhovenCBChristine Van Broeckhoven
- Peter Paul De DeynPDPeter Paul De Deyn
Open Access
- 22 June 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 130 (9) , 2320-2326
Abstract
The CSF biomarkers β-amyloid peptide (Aβ1–42), total tau protein (T-tau) and tau phosphorylated at threonine 181 (P-tau181P) were determined in autopsy-confirmed Alzheimer's disease patients in order to study possible associations with the ε4 allele of APOE and density and spread of plaques (SP) and tangles (NFT). CSF levels of Aβ1–42, T-tau and P-tau181P were determined in 50 Alzheimer's disease patients using commercially available single parameter ELISA kits (INNOTEST®). Genomic DNA was extracted from whole blood and the APOE genotype was determined using standard methods. Tangle burden was assessed by means of Braak's NFT stages (I–VI), whereas the plaque burden was assessed by means of Braak's SP stages (A–C). CSF biomarker levels were not different when comparing ε4 carriers (n = 21) and non-carriers (n = 29) (P > 0.05 for all comparisons). No significant correlations between the number of ε4 alleles (0, 1 or 2) and CSF levels of Aβ1–42 (Spearman Rank Order: r = −0.057, P = 0.695), T-tau (r = 0.104, P = 0.472) and P-tau181P (r = 0.062, P = 0.668) were found. Braak's SP (Aβ1–42: r = −0.155, P = 0.280; T-tau: r = −0.044, P = 0.763; P-tau181P: r = −0.010, P = 0.947) and NFT (Aβ1–42: r = −0.145, P = 0.315; T-tau: r = 0.117, P = 0.415; P-tau181P: r = 0.150, P = 0.296) stages were not significantly correlated with CSF biomarker levels. In conclusion, CSF levels of Aβ1–42, T-tau and P-tau181P were not associated with ε4, tangle or plaque burden in 50 autopsy-confirmed Alzheimer's disease patients. In the light of future biomarker applications like monitoring of disease progression and as allocortical neuropathological changes significantly contribute to clinical symptoms, the concept of in vivo surrogate biomarkers should be further explored.Keywords
This publication has 25 references indexed in Scilit:
- CSF biomarkers for mild cognitive impairment and early Alzheimer's diseaseClinical Neurology and Neurosurgery, 2005
- Cerebrospinal fluid β-amyloid1–42 and tau in control subjects at risk for Alzheimer’s disease: The effect of APOE ε4 alleleBiological Psychiatry, 2004
- Cerebrospinal Fluid Tau and β-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive ImpairmentArchives of Neurology, 2002
- CSF levels of tau, β-amyloid 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal agingJournal of Neural Transmission, 2000
- Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer DiseaseArchives of Neurology, 2000
- Neuropathology of Alzheimer’s disease: what is new since A. Alzheimer?European Archives of Psychiatry and Clinical Neuroscience, 1999
- Apolipoprotein E ?4 allele in association with global cognitive performance and CSF markers in Alzheimer's diseaseInternational Journal of Geriatric Psychiatry, 1998
- Risk Estimates of Dementia by Apolipoprotein E Genotypes From a Population-Based Incidence Study: The Rotterdam StudyArchives of Neurology, 1998
- High Cerebrospinal Fluid Tau and Low Amyloid β42 Levels in the Clinical Diagnosis of Alzheimer Disease and Relation to Apolipoprotein E GenotypeArchives of Neurology, 1998
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991